DRDennis F. G. Remst

Dennis F. G. Remst

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dennis F. G. Remst has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Immunoglobulin constant domains as targets for T-cell receptor–based treatment of multiple myeloma

    by Miranda H. Meeuwsen, Anne K. Wouters, Johannes C. Wellershoff, Tassilo L. A. Wachsmann, Dennis F. G. Remst, Renate S. Hagedoorn, Michel G. D. Kester, Dirk M. van der Steen, Arnoud H. de Ru, Els P. van Hees, et al.

    Despite major progress with chimeric antigen receptor T-cell therapy, multiple myeloma (MM) remains largely incurable and most patients relapse. To broaden therapeutic options and overcome antigen escape, we explored T-cell receptor (TCR)–based targeting of intracellular antigens derived from immunoglobulin heavy chain constant domains. Using HLA class-I peptidomics, we identified 9 immunoglobulin G (IgG)– or IgA-derived peptides presented by common HLA alleles (HLA-A∗01:01, HLA-A∗02:01, HLA-A∗03:01, and HLA-B∗07:02). High-avidity T-cell clones recognizing 4 of these epitopes were isolated from HLA-mismatched healthy donors. The transfer of these immunoglobulin-specific TCRs into donor T cells conferred potent and selective recognition of IgG- or IgA-expressing MM cell lines, sparing antigen-negative cells. Safety profiling confirmed strict HLA-restricted specificity without cross-reactivity toward other HLA alleles, non–B-lineage tumor cell lines, or healthy tissues, except for the depletion of isotype-matched B cells. Immunoglobulin-TCR T cells efficiently lysed patient-derived MM cells ex vivo and eradicated established IgA- or IgG-expressing MM tumors in murine xenograft models. Mechanistic studies revealed that dendritic cells could cross-present immunoglobulin peptides at high serum concentrations, potentially enhancing T-cell activation in vivo. Importantly, subtype-specific depletion of B cells implies that immunoglobulin-TCR T-cell therapy could partly preserve humoral immunity, reducing the need for antibody replacement compared with pan–B-cell depletion strategies. Collectively, these findings establish immunoglobulin heavy chain constant domains as promising targets for TCR-based cellular immunotherapy in MM and potentially other immunoglobulin-producing malignancies or autoantibody-mediated autoimmune diseases.


  • Open Access

    Chimeric HLA Antibody Receptor T Cells to Specifically Eliminate HLA-DQ–Specific B Cells

    by Carolt Arana, Ilse Gille, Renate Hagedoorn, Ainhoa García-Busquets, Hannah C.M. Schenk, Sergi Betriu, Dennis F.G. Remst, Ellen M.W. van der Meer-Prins, Yvonne J.H. de Vaal, Kim H. Voogt-Bakker, et al.

    Key Points: HLA-DQ2/DQ7 chimeric HLA antibody receptor T cells, the first HLA class II chimeric HLA antibody receptor T cells, selectively eliminated cognate HLA-DQ–specific B cells in a dose-dependent manner. HLA-DQ chimeric HLA antibody receptor T cells efficiently depleted HLA-DQ–specific B cells with corresponding specificity in vivo . Chimeric HLA antibody receptor T-cell therapy expanded donor availability through targeted desensitization and represented a potential antigen-specific antibody-mediated rejection therapy. Background: Chimeric antigen receptor T-cell therapy has revolutionized the treatment of hematologic malignancies by effectively eliminating tumor cells. In the field of kidney transplantation, comparable cellular therapies are being explored to facilitate transplantation and prevent graft rejection. Chimeric HLA antibody receptor (CHAR) T cells are a promising therapy for eliminating HLA-specific B cells in sensitized patients and potentially ameliorating antibody-mediated rejection. We previously demonstrated that HLA class I CHAR T cells selectively eliminated HLA class I–specific B cells with high specificity. Since HLA sensitization is most often directed against HLA-DQ of the allograft, we developed HLA-DQ2 and HLA-DQ7 CHAR T cells to target B cells with corresponding HLA specificity. Methods: We designed viral vectors encoding HLA-DQ CHARs composed of HLA-DQA1*05:01 α chain with either HLA-DQB1*02:01 (HLA-DQ2) or HLA-DQB1*03:01 (HLA-DQ7) β chains, class II–associated invariant chain peptide, and intracellular 4-1BB costimulatory and CD3ζ signaling domains. Upon production of HLA-DQ CHAR T cells, we evaluated CHAR expression, cytotoxic activity, production of cytokines and cytotoxic mediators, and sensitivity to immunosuppressive drugs in in vitro models. We further assessed the cytotoxic activity of HLA-DQ CHAR T cells in an immunodeficient mouse model and in primary material from sensitized individuals. Results: CHAR-transduced Jurkat triple parameter reporter cells expressing reporter constructs for T-cell activation markers showed robust activation upon specific stimulation. Primary CD8 + T cells expressing HLA-DQ2 and HLA-DQ7 CHAR molecules specifically eliminated HLA-DQ2– or HLA-DQ7–specific B cells, respectively, and produced interferon gamma, soluble Fas ligand, perforin, and granzyme B. Maintenance immunosuppressive drug regimens initiated at the time of coincubation with target cells had limited effects on CHAR T-cell functionality. Finally, HLA-DQ CHAR T cells effectively eliminated HLA-DQ–specific B cells in an in vivo mouse model, as well as in primary material from sensitized individuals. Conclusions: HLA-DQ2 and HLA-DQ7 CHAR T cells, the first HLA class II CHAR T cells, selectively and effectively eliminated corresponding HLA-DQ–specific B cells in vitro , in vivo , and in primary material from sensitized individuals.

  • Open Access

    Supplementary Movie 1 - TEM assay MOCK transduced endothelial cells and CD8 T cells from VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation

    by Sietse J. Luk, Rouven Schoppmeyer, Marieke E. Ijsselsteijn, Antonios Somarakis, Ibtissam Acem, Dennis F.G. Remst, Daan T. Cox, Cornelis A.M. van Bergen, Inge Briaire-De Bruijn, Max L.B. Grönloh, et al.

    Movie of a transendothelial migration assay using MOCK transduced endothelial cells and CD8 T cells that were derived from healthy PBMCs. Total duration of the movie is 20 minutes. Each datapoint in figure 5 and supplementary figures 7 and 8 is derived from the quantification of migration of a single video.

  • Open Access

    Supplementary Figures and Tables from VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation

    by Sietse J. Luk, Rouven Schoppmeyer, Marieke E. Ijsselsteijn, Antonios Somarakis, Ibtissam Acem, Dennis F.G. Remst, Daan T. Cox, Cornelis A.M. van Bergen, Inge Briaire-De Bruijn, Max L.B. Grönloh, et al.

    Supplementary Figures and Tables

  • Open Access

    Supplementary Movie 2 - TEM assay VISTA transduced endothelial cells and CD8 T cells from VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation

    by Sietse J. Luk, Rouven Schoppmeyer, Marieke E. Ijsselsteijn, Antonios Somarakis, Ibtissam Acem, Dennis F.G. Remst, Daan T. Cox, Cornelis A.M. van Bergen, Inge Briaire-De Bruijn, Max L.B. Grönloh, et al.

    Movie of a transendothelial migration assay using VISTA transduced endothelial cells and total CD8 T cells that were derived from healthy PBMCs. Total duration of the movie is 20 minutes. Each datapoint in figure 5 and supplementary figures 7 and 8 is derived from the quantification of migration of a single video.

  • Open Access

    Data from VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation

    by Sietse J. Luk, Rouven Schoppmeyer, Marieke E. Ijsselsteijn, Antonios Somarakis, Ibtissam Acem, Dennis F.G. Remst, Daan T. Cox, Cornelis A.M. van Bergen, Inge Briaire-De Bruijn, Max L.B. Grönloh, et al.

    Cancers evade T-cell immunity by several mechanisms such as secretion of anti-inflammatory cytokines, down regulation of antigen presentation machinery, upregulation of immune checkpoint molecules, and exclusion of T cells from tumor tissues. The distribution and function of immune checkpoint molecules on tumor cells and tumor-infiltrating leukocytes is well established, but less is known about their impact on intratumoral endothelial cells. Here, we demonstrated that V-domain Ig suppressor of T-cell activation (VISTA), a PD-L1 homolog, was highly expressed on endothelial cells in synovial sarcoma, subsets of different carcinomas, and immune-privileged tissues. We created an ex vivo model of the human vasculature and demonstrated that expression of VISTA on endothelial cells selectively prevented T-cell transmigration over endothelial layers under physiologic flow conditions, whereas it does not affect migration of other immune cell types. Furthermore, endothelial VISTA correlated with reduced infiltration of T cells and poor prognosis in metastatic synovial sarcoma. In endothelial cells, we detected VISTA on the plasma membrane and in recycling endosomes, and its expression was upregulated by cancer cell–secreted factors in a VEGF-A–dependent manner. Our study reveals that endothelial VISTA is upregulated by cancer-secreted factors and that it regulates T-cell accessibility to cancer and healthy tissues. This newly identified mechanism should be considered when using immunotherapeutic approaches aimed at unleashing T cell–mediated cancer immunity.

  • Open Access

    Supplementary Table S3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer

    by Rosa A. van Amerongen, Sander Tuit, Dennis F.G. Remst, Anne K. Wouters, Sterre L. Siekman, Renate S. Hagedoorn, Dirk M. van der Steen, Michel G.D. Kester, Arnoud H. de Ru, Geertje van der Horst, et al.

    Supplementary Table S3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer

  • Open Access

    Supplementary Table S4 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer

    by Rosa A. van Amerongen, Sander Tuit, Dennis F.G. Remst, Anne K. Wouters, Sterre L. Siekman, Renate S. Hagedoorn, Dirk M. van der Steen, Michel G.D. Kester, Arnoud H. de Ru, Geertje van der Horst, et al.

  • Open Access

    Supplemental Figure 8 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer

    by Rosa A. van Amerongen, Sander Tuit, Dennis F.G. Remst, Anne K. Wouters, Sterre L. Siekman, Renate S. Hagedoorn, Dirk M. van der Steen, Michel G.D. Kester, Arnoud H. de Ru, Geertje van der Horst, et al.

    Boxplots depicting (A) CDH23 and (B) LOXHD1 expression in various tumor types (TCGA data n=30) and healthy tissue types (TCGA data n=30 and GTEx data n=5-20). Red, green and white boxplots represent tumor types (TCGA data), healthy tissues (TCGA data), and healthy tissues (GTEx), respectively. Boxplots extend from first to third quartile, the horizontal line represent the median expression value. The whiskers represent the minimum and maximum expression value (1.5 IQR from the first and third quartile). Outliers are defined as being 1.5*IQR or more above the third or below the first quartile, respectively. Y-axis abbreviations are described in supplemental table 1. (FC: fold change, GTEx: genotype-tissue expression, IQR: interquartile range, log2-CPM: log2-transformed counts per million, TCGA: The cancer genome atlas)

  • Open Access

    Supplementary Table S1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer

    by Rosa A. van Amerongen, Sander Tuit, Dennis F.G. Remst, Anne K. Wouters, Sterre L. Siekman, Renate S. Hagedoorn, Dirk M. van der Steen, Michel G.D. Kester, Arnoud H. de Ru, Geertje van der Horst, et al.

    Supplementary Table S1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer